OrganOx

Founded 2008
Employees 50+
Primary contact
Oxford Science Park, Magdalen Centre
Robert Robinson Avenue
OX4 4GA Oxford
United Kingdom
+44 (0) 1865 504024
OrganOx is a leader in normothermic machine perfusion dedicated to saving lives by making every donated organ count. The company's OrganOx metra solution uses proprietary Normothermic Machine Perfusion (NMP) technology to preserve donor livers in a functioning state for up to 24 hours prior to transplant. It is a fully automated device that enables continuous monitoring and evaluation of the liver, empowering surgeons to make evidence-based decisions on whether to transplant a donor organ — enabling viability testing and transplant of previously declined organs. The metra is commercially available in Europe (CE Mark) and the United States (FDA-approved).
Founded 2008
Employees 50+
Primary contact
Oxford Science Park, Magdalen Centre
Robert Robinson Avenue
OX4 4GA Oxford
United Kingdom
+44 (0) 1865 504024

Funding 💰

Total £41.3M
Last round 🔗 £25M
Growth
July 17, 2023.
Select investors Oxford Investment Consultants, Lauxera Capital Partners, Business Growth Fund, Oxford Technology Management, Technikos, Longwall Venture Partners, Amadeus Capital Partners, Royal Society Enterprise Fund

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Solving the problem: Conventional cold preservation involves the storage of the liver at 4˚C, using a non-physiological perfusion solution that aims to minimize liver decay. By contrast, warm preservation seeks to re-create an environment that mimics the human body by continuously perfusing at physiological pressures and flows with oxygen-carrying red cells at 37˚C and providing nutrition. The liver is, therefore, functional during the preservation period, producing bile, metabolizing glucose and maintaining a physiological pH. This enables an objective assessment of organ performance prior to transplant, extended preservation times, and the potential use of organs that are presently being discarded.
  • Years in the making: The core technology employed by the OrganOx metra has been in development for over 15 years. During this time, both founders (Professor Peter Friend and Professor Constantin Coussios) have driven the development of organ preservation and maintenance, formerly at the University of Cambridge and latterly at the University of Oxford.
  • It works: With more than 2,500 OrganOx-supported liver transplants (July 2023) successfully performed in Europe, the US, and Australia, the rapid growth in the use of metra has been driven by the ability to preserve livers for longer periods than the current gold standard, enabling surgeons to assess liver function before transplantation. The metra technology also enables transplants to be routinely scheduled during the working day, avoiding overnight surgery, which improves the surgical team's working schedule.

Video ▶️

Quotes 💬

We are thrilled to continue to support OrganOx through a crucial time in its development. OrganOx is addressing a clear unmet need in the transplant market with its normothermic perfusion devices, improving the viability and supply of donor organs. This ground-breaking technology has the ability to significantly transform the lives of many thousands of people that spend several years on the organ transplant waiting list. We look forward to supporting the team as they seek US market approval and expand the reach of their lifesaving technology to the patients that need it.
George Robinson, Founding Partner at Oxford Investment Consultants LLP 🔗
Last update: July 26, 2023